Clinical trial NCT03692780: Careseng 1370 for Chemotherapy-Induced Myelosuppression
Official title: A Phase I Dose-Finding Followed by Phase IIa Randomized, Double-Blind, Placebo-Controlled, Parallel, Add-on to Cisplatin Plus Docetaxel Study to Evaluate the Safety, Tolerability and Efficacy Profiles of Careseng 1370 to Treat Chemotherapy-Induced Myelosuppression in Advanced Non-Small Cell Lung Cancer (NSCLC) Subjects
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Chemotherapy-Induced Myelosuppression
Lead sponsor: Careseng Biotech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-10-02
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of Careseng 1370 in subjects with advanced NSCLC.


Eligibility criteria: Inclusion Criteria:

1. Of either gender aged at least 20 years old
2. Histologically or cytologically confirmed unresectable, locally advanced, metastatic untreated NSCLC and can be accurately assessed by computed tomography/magnetic resonance imaging (CT/MRI) scan (RECIST v1.1) for which regimen of cisplatin + docetaxel is arranged by the investigator; no prior chemotherapy treatment for this disease will be allowed.
3. ECOG performance status score ≤2 and life expectancy ≥12 months
4. Dated and signed informed consent

Exclusion Criteria:

1. Had chemotherapy, therapeutic radiotherapy, or other therapy for NSCLC within 6 weeks before Screening visit
2. Has undergone major surgery within 4 weeks before Screening visit
3. With contraindications to MRI
4. Has elective or planned surgery to be conducted during the trial
5. Has documented brain or leptomeningeal metastases or any cancer other than NSCLC
6. Inadequate hematologic function, as defined by: absolute neutrophil count (ANC) ≤ 1,500/µL; hemoglobin concentration \< 10.0 g/dL; and platelet count ≤ 100,000/µL
7. Inadequate hepatic function, as defined by: total bilirubin level \> ULN; AST or ALT \> 1.5 x ULN; gamma-GT \> 2.5 x ULN; ALP \> 2.5 x ULN.
8. Inadequate renal function, as defined by: serum creatinine level \> 1.5 x ULN; or calculated serum creatinine clearance (Cockcroft-Gault) \< 50 mL/min
9. Urinary protein \>1+ on dipstick, edema or serum albumin \< lower level of normal
10. Any other ≥ grade 3 laboratory abnormality at baseline
11. Inadequate coagulation function, as defined by: INR \> 1.5 x ULN or aPTT \> 1.5 x ULN
12. Male subject with female spouse/partners who are of childbearing potential refuses to adopt highly effective contraceptives from Screening visit until 7 days after end of study treatment
13. Female subjects with childbearing potential who is pregnant (confirmed by urine or serum pregnancy test) or lactating, refuses to adopt highly effective contraceptives, if heterosexually active, from Screening visit until 7 days after end of study treatment
14. Requirement of anticoagulants, antiplatelet treatments (e.g., warfarin, heparins) from Screening visit until Final visit
15. History of human immunodeficiency virus (HIV) infection
16. Has experienced any grade 3 or 4 gastrointestinal bleeding within 12 weeks before Screening visit
17. Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess \<6 months before Screening visit, or the subject has a history of poorly controlled or recurrent inflammatory bowel disease (including Crohn's disease or ulcerative colitis)
18. Has participated in a clinical study within 4 weeks prior to Screening visit
19. Has a known allergy to investigational product Careseng 1370, matched placebo, cisplatin, docetaxel or their excipients. If there is suspicion that the subject may have an allergy, the subject should be excluded.
20. Has known alcohol or drug dependency
21. Requirement for ongoing immunosuppressive agents (including azathioprine, mycophenolate, cyclophosphamide, chlorambucil, methotrexate, cyclosporine) or systemic steroid with equivalent dosage higher than prednisolone 30 mg/day for more than 14 days
22. Significant cardiovascular disease, including:

    1. History of New York Heart Association (NYHA) class III or IV congestive heart failure
    2. Ongoing uncontrolled hypertension
    3. History of congenital long QT syndrome
    4. Ongoing prolonged corrected QT (QTc) interval defined as at least 450 msec
    5. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
23. Uncontrolled psychiatric disorder or altered mental status precluding informed consent or necessary testing per investigator's discretion
24. Consumption of herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) within 2 weeks prior to the start of cisplatin + docetaxel or Careseng 1370/matched placebo administration
25. Is not considered to be suitable for this study, in the opinion of the investigator

Primary outcomes:
measure: Maximum change of absolute neutrophil count (ANC) up to End of Treatment visit
timeFrame: Day 1, 8, 15 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
Secondary outcomes:
measure: Proportion of subjects with anemia, neutropenia, or thrombocytopenia of all grades at post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Maximum change and by visit change in white blood cell (WBC) count from baseline to post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Maximum change and by visit change in platelet count from baseline to post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Maximum change and by visit change in red blood cell (RBC) count from baseline to post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Maximum change and by visit change in serum C-reactive protein (CRP) level from baseline to post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Maximum change and by visit change in absolute neutrophil count (ANC) from baseline to post-treatment visits
timeFrame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
measure: Objective response rate (ORR) defined as the proportion of subjects with CR or PR as best overall response evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 on MRI or CT results
timeFrame: Day 1, 43, 85
measure: Disease control rate (DCR) defined as the proportion of subjects with CR, PR, or SD as best overall response evaluated according to RECIST criteria version 1.1 on MRI or CT results
timeFrame: Day 1, 43, 85
measure: Proportion of subjects with complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) as best overall response evaluated according to RECIST criteria version 1.1 on MRI or CT results
timeFrame: Day 1, 43, 85
measure: Change in quality of life assessed by the Functional Assessment of Cancer Therapy Lung Cancer (FACT-L) total score from baseline to post-treatment visits
timeFrame: Day 1, 22, 43, 64, 85
Other outcomes:
Locations:
Study officials:
References: